Inhibition of proteasome deubiquitinase activity: a strategy to overcome resistance to conventional proteasome inhibitors?

Although more traditionally associated with degradation and maintenance of protein homeostasis, the ubiquitin-proteasome system (UPS) has emerged as a critical component in the regulation of cancer cell growth and survival. The development of inhibitors that block the proteolytic activities of the proteasome have highlighted its suitability as a bona fide anti-cancer drug target. However, key determinants including the development of drug resistance and dose-limiting toxicity call for the identification of alternative components of the UPS for novel drug targeting.

Source: Drug Resistance Updates - July 6, 2015 Category: Drugs & Pharmacology Authors: Karthik Selvaraju, Magdalena Mazurkiewicz, Xin Wang, Joachim Gullbo, Stig Linder, Pádraig D’Arcy Source Type: research